Last reviewed · How we verify
Nicotine Replacement Products
Nicotine Replacement Products is a Small molecule drug developed by Joseph Valentino, MD. It is currently in Phase 2 development. Also known as: nicotine gum, nicotine losenges, nicotine spray.
Nicotine Replacement Products, specifically in the form of gum, are used to treat conditions such as cigarette smoking, tobacco dependence, and opioid use disorder, as well as betel nut cessation. These products contain the small molecule nicotine, which is administered through a non-medicated or medicated gum formulation, typically in doses of 2mg or 4mg.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Nicotine Replacement Products |
|---|---|
| Also known as | nicotine gum, nicotine losenges, nicotine spray |
| Sponsor | Joseph Valentino, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder (PHASE2)
- Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation (PHASE4)
- STEPS: Substance Use Trial of E-cigarettes or Pharmacotherapy for Smoking (NA)
- Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening (NA)
- Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (PHASE2)
- C-Raven, a Virtual Tobacco Cessation Intervention in Residency Clinics (PHASE4)
- C-Raven, a Virtual Tobacco Cessation Intervention in the Community (PHASE4)
- Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicotine Replacement Products CI brief — competitive landscape report
- Nicotine Replacement Products updates RSS · CI watch RSS
- Joseph Valentino, MD portfolio CI
Frequently asked questions about Nicotine Replacement Products
What is Nicotine Replacement Products?
Who makes Nicotine Replacement Products?
Is Nicotine Replacement Products also known as anything else?
What development phase is Nicotine Replacement Products in?
Related
- Manufacturer: Joseph Valentino, MD — full pipeline
- Also known as: nicotine gum, nicotine losenges, nicotine spray
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing